Official Title

Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
  • Phase

    N/A
  • Study Type

    Interventional
  • Status

    Withdrawn
  • Intervention/Treatment

    ga 68-edotreotide ...
  • Study Participants

    0
This pilot clinical trial studies gallium Ga 68-edotreotide (68Ga-DOTATOC) positron emission tomography (PET)/computed tomography (CT) in finding brain tumors in younger patients. Diagnostic procedures, such as gallium Ga 68-edotreotide PET/CT imaging, may help find and diagnose brain tumors.
PRIMARY OBJECTIVES:

I. To determine if 68Ga-DOTATOC (gallium Ga 68-edotreotide) PET when combined with magnetic resonance imaging (MRI) will differentiate embryonal tumors such as medulloblastoma and supratentorial primitive neuroectodermal tumor (PNET) from the low and high grade gliomas.

II. To determine if 68Ga-DOTATOC PET will aid in the identification of residual tumor post operatively in those patients who were 68Ga-DOTATOC PET positive prior to surgery.

OUTLINE:

Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery.
Study Started
Sep 30
2013
Primary Completion
Mar 31
2017
Study Completion
Mar 31
2017
Last Update
Apr 28
2017

Radiation gallium Ga 68-edotreotide

Undergo gallium Ga 68-edotreotide PET/CT

  • Other names: Ga-68 DOTA0-Tyr3-octreotide, Ga-68 DOTATOC

Procedure positron emission tomography

Undergo gallium Ga 68-edotreotide PET/CT

  • Other names: FDG-PET, PET, PET scan, tomography, emission computed

Procedure computed tomography

Undergo gallium Ga 68-edotreotide PET/CT

  • Other names: tomography, computed

Other laboratory biomarker analysis

Correlative studies

Diagnostic (gallium Ga 68-edotreotide PET/CT) Experimental

Patients undergo gallium Ga 68-edotreotide PET/CT at baseline and 1-30 days after surgery. Interventions: gallium Ga 68-edotreotide, positron emission tomography, computed tomography, laboratory biomarker analysis

Criteria

Inclusion Criteria:

Patients presenting with brain tumors will be eligible for this study
Eligible subjects must be able and willing to undergo the procedures of the study
Electronic version of pre-surgery MRI must be available for co-registration purposes
Fresh frozen tumor, and/or paraffin block of biopsy or resected tumor is recommended, but not required to determine expression of somatostatin receptors in tumor by immunohistochemistry and/or quantitative polymerase chain reaction (qPCR)

Exclusion Criteria:

Women who are pregnant or breastfeeding
Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin of body that would preclude obtaining an MRI as part of the initial study evaluation
Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons
Presence of any additional medical condition such as inter-current illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance
No Results Posted